BC
MCID: BRS047
MIFTS: 100

Breast Cancer (BC) malady

Categories: Genetic diseases, Rare diseases, Cancer diseases, Reproductive diseases

Aliases & Classifications for Breast Cancer

Aliases & Descriptions for Breast Cancer:

Name: Breast Cancer 54 12 25 66 13 52 41 3 14
Breast Carcinoma 12 25 66 52 14 69
Male Breast Cancer 12 50 41 14
Malignant Neoplasm of Breast 12 25 69
Breast Lobular Carcinoma 12 29 14
Breast Cancer, Lobular 54 38 24
Mammary Carcinoma 12 66 14
Malignant Neoplasm of Male Breast 12 69
Invasive Ductal Breast Carcinoma 52 69
Breast Cancer, Invasive Ductal 54 38
Breast Cancer Familial Male 66 29
Breast Cancer, Early-Onset 54 29
Breast Cancer, Somatic 54 24
Breast Cancer Familial 66 29
Primary Breast Cancer 12 14
Male Breast Carcinoma 50 29
Breast Cancer, Male 54 50
Cancer of Breast 25 29
Mammary Cancer 12 25
Mammary Tumor 12 52
Primary Malignant Neoplasm of Breast 69
Breast Cancer, Protection Against 54
Malignant Tumor of the Breast 12
Breast Cancer Susceptibility 54
Malignant Tumor of Breast 25
Animal Mammary Neoplasms 69
Carcinoma of Male Breast 69
Neoplasm of Male Breast 12
Breast Cancer, Familial 25
Breast Neoplasms, Male 42
Breast Male Carcinoma 52
Breast Cancer in Men 50
Carcinoma of Breast 12
Mammary Neoplasms 69
Mammary Neoplasm 12
Breast Neoplasms 42
Breast Tumor 12
Bc 66

Characteristics:

HPO:

32
breast cancer:
Inheritance autosomal dominant inheritance heterogeneous


Classifications:



Summaries for Breast Cancer

MedlinePlus : 41 breast cancer affects one in eight women during their lives. no one knows why some women get breast cancer, but there are many risk factors. risks that you cannot change include age - the risk rises as you get older genes - two genes, brca1 and brca2, greatly increase the risk. women who have family members with breast or ovarian cancer may wish to be tested for the genes. personal factors - beginning periods before age 12 or going through menopause after age 55 other risks include obesity, using hormone replacement therapy (also called menopausal hormone therapy), taking birth control pills, drinking alcohol, not having children or having your first child after age 35, and having dense breasts. symptoms of breast cancer may include a lump in the breast, a change in size or shape of the breast, and discharge from a nipple. breast self-exams and mammography can help find breast cancer early, when it is most treatable. one possible treatment is surgery. it could be a lumpectomy or a mastectomy. other treatments include radiation therapy, chemotherapy, hormone therapy, and targeted therapy. targeted therapy uses substances that attack cancer cells without harming normal cells. men can have breast cancer, too, but it is rare. nih: national cancer institute

MalaCards based summary : Breast Cancer, also known as breast carcinoma, is related to estrogen-receptor positive breast cancer and progesterone-receptor positive breast cancer, and has symptoms including breast carcinoma, pelvic pain and lameness, animal. An important gene associated with Breast Cancer is BRCA2 (BRCA2, DNA Repair Associated), and among its related pathways/superpathways are Cell Cycle, Mitotic and DNA Double-Strand Break Repair. The drugs Abraxane and Afinitor have been mentioned in the context of this disorder. Affiliated tissues include breast, bone and lymph node, and related phenotypes are Decreased homologous recombination repair frequency and cellular

Disease Ontology : 12 A thoracic cancer that originates in the mammary gland.

Genetics Home Reference : 25 Breast cancer is a disease in which certain cells in the breast become abnormal and multiply uncontrollably to form a tumor. Although breast cancer is much more common in women, this form of cancer can also develop in men. In both women and men, the most common form of breast cancer begins in cells lining the milk ducts (ductal cancer). In women, cancer can also develop in the glands that produce milk (lobular cancer). Most men have little or no lobular tissue, so lobular cancer in men is very rare.

OMIM : 54 Breast cancer (referring to mammary carcinoma, not mammary sarcoma) is histopathologically and almost certainly... (114480) more...

CDC : 3 Breast cancer is a group of diseases that affects breast tissue. Both women and men can get breast cancer, though it is much more common in women. Other than skin cancer, breast cancer is the most common cancer among women in the United States. Some women are at higher risk for breast cancer than others because of their personal or family medical history or because of certain changes in their genes.

Novus Biologicals : 53 Breast cancer is a malignant tumor that originates from breast tissue cells. Although most breast cancers initiate in the cells that line the breast ducts, some begin in the breast lobules and other tissues. As with all cancers, there is a genetic and environmental component of developing breast cancer. Women with defects in the BRCA1 and BRCA2 genes have up to an 80% chance of getting breast cancer. Research has also found that defects in the ErbB-2 gene lead to increased levels of the protein cyclin D1. Cyclin D1 then activates CDK4, which causes proliferation of cellular division. Blocking CDK4 activity may lead to effective breast cancer treatments.

UniProtKB/Swiss-Prot : 66 Breast cancer: A common malignancy originating from breast epithelial tissue. Breast neoplasms can be distinguished by their histologic pattern. Invasive ductal carcinoma is by far the most common type. Breast cancer is etiologically and genetically heterogeneous. Important genetic factors have been indicated by familial occurrence and bilateral involvement. Mutations at more than one locus can be involved in different families or even in the same case.

Wikipedia : 71 Breast cancer is cancer that develops from breast tissue. Signs of breast cancer may include a lump in... more...

Related Diseases for Breast Cancer

Diseases in the Breast Cancer family:

Breast Benign Neoplasm Inflammatory Breast Carcinoma
Sporadic Breast Cancer Breast Carcinoma in Situ
Familial Breast Cancer Bard1-Related Susceptibility to Breast Cancer
Brip1-Related Breast Cancer Chek2-Related Susceptibility to Breast Cancer
Rad51-Related Susceptibility to Breast Cancer

Diseases related to Breast Cancer via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 660)
id Related Disease Score Top Affiliating Genes
1 estrogen-receptor positive breast cancer 34.0 BRCA1 BRCA2 CDH1 TP53
2 progesterone-receptor positive breast cancer 34.0 AKT1 BRCA1 BRCA2 CDH1 TP53
3 progesterone-receptor negative breast cancer 33.7 AKT1 PIK3CA TP53
4 colorectal cancer 31.5 AKT1 ATM BRCA1 BRCA2 CASP8 CDH1
5 nasopharyngeal carcinoma 30.7 ATM BRCA1 BRCA2 CHEK2 TP53
6 pyomyositis 30.5 BRCA1 BRCA2 CDH1 TP53
7 linitis plastica 30.4 CDH1 TP53
8 bacteremia 30.3 BRCA1 BRCA2 PALB2
9 hidradenoma 30.1 BRCA1 BRCA2 KRAS TP53
10 cystadenoma 29.6 AKT1 CASP8 TP53
11 familial breast cancer 12.4
12 bilateral breast cancer 12.2
13 sporadic breast cancer 12.0
14 estrogen-receptor negative breast cancer 12.0
15 female breast cancer 11.9
16 triple-receptor negative breast cancer 11.9
17 inflammatory breast carcinoma 11.9
18 androgen insensitivity, partial, with or without breast cancer 11.8
19 her2-receptor positive breast cancer 11.8
20 her2-receptor negative breast cancer 11.8
21 breast cancer, childhood 11.8
22 bard1-related susceptibility to breast cancer 11.7
23 breast cancer susceptibility, xrcc3-related 11.7
24 brip1-related breast cancer 11.7
25 chek2-related susceptibility to breast cancer 11.7
26 rad51-related susceptibility to breast cancer 11.7
27 brca1 hereditary breast and ovarian cancer syndrome 11.4
28 brca2 hereditary breast and ovarian cancer syndrome 11.4
29 gastric cancer risk after h. pylori infection 11.4
30 breast metaplastic carcinoma 11.4
31 breast-ovarian cancer, familial 4 11.4
32 breast-ovarian cancer, familial, 1 11.4
33 breast-ovarian cancer, familial, 2 11.4
34 breast-ovarian cancer, familial 3 11.4
35 li-fraumeni syndrome 11.4
36 systemic lupus erythematosus with nephritis 2 11.2 AKT1 ATM BARD1 BRCA1 BRCA2 BRIP1
37 paraneoplastic cerebellar degeneration 11.2
38 breast fibroadenoma 11.2
39 granulomatous lobular mastitis 11.2
40 brittle cornea syndrome 2 11.2
41 adenocarcinoma 11.1
42 paraneoplastic syndromes 11.1
43 breast sarcoma 11.0
44 familial glucocorticoid deficiency 11.0 ATM BARD1 BRCA1 BRCA2 BRIP1 CASP8
45 breast scirrhous carcinoma 10.9
46 breast mucinous carcinoma 10.9
47 breast squamous cell carcinoma 10.9
48 basal cell carcinoma 7 10.9 AKT1 ATM BRCA1 BRCA2 CASP8 CDH1
49 split-hand/foot malformation with long bone deficiency 1 10.9 AKT1 BRCA1 BRCA2 CASP8 CDH1 CHEK2
50 obesity 10.9

Graphical network of the top 20 diseases related to Breast Cancer:



Diseases related to Breast Cancer

Symptoms & Phenotypes for Breast Cancer

Symptoms by clinical synopsis from OMIM:

114480

Clinical features from OMIM:

114480

Human phenotypes related to Breast Cancer:

32
id Description HPO Frequency HPO Source Accession
1 breast carcinoma 32 HP:0003002

UMLS symptoms related to Breast Cancer:


pelvic pain, lameness, animal, pain

GenomeRNAi Phenotypes related to Breast Cancer according to GeneCards Suite gene sharing:

26
id Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Decreased homologous recombination repair frequency GR00151-A-1 10.79 RAD51 BARD1 BRCA1
2 Decreased homologous recombination repair frequency GR00151-A-2 10.79 RAD51 BRCA1
3 Decreased homologous recombination repair frequency GR00236-A-1 10.79 TSG101 BARD1 BRCA1 BRCA2 PALB2 RAD51
4 Decreased homologous recombination repair frequency GR00236-A-2 10.79 TSG101 ATM BARD1 BRCA1 BRCA2 PALB2
5 Decreased homologous recombination repair frequency GR00236-A-3 10.79 RAD51 BARD1 BRCA1 BRCA2 PALB2
6 Decreased shRNA abundance (Z-score < -2) GR00366-A-116 10.48 PIK3CA BRCA1
7 Decreased shRNA abundance (Z-score < -2) GR00366-A-117 10.48 KRAS
8 Decreased shRNA abundance (Z-score < -2) GR00366-A-119 10.48 TSG101
9 Decreased shRNA abundance (Z-score < -2) GR00366-A-139 10.48 BRCA1
10 Decreased shRNA abundance (Z-score < -2) GR00366-A-145 10.48 KRAS
11 Decreased shRNA abundance (Z-score < -2) GR00366-A-165 10.48 KRAS
12 Decreased shRNA abundance (Z-score < -2) GR00366-A-193 10.48 KRAS
13 Decreased shRNA abundance (Z-score < -2) GR00366-A-204 10.48 BRCA1
14 Decreased shRNA abundance (Z-score < -2) GR00366-A-211 10.48 BRCA1
15 Decreased shRNA abundance (Z-score < -2) GR00366-A-216 10.48 KRAS PIK3CA TSG101
16 Decreased shRNA abundance (Z-score < -2) GR00366-A-27 10.48 KRAS
17 Decreased shRNA abundance (Z-score < -2) GR00366-A-33 10.48 KRAS
18 Decreased shRNA abundance (Z-score < -2) GR00366-A-40 10.48 PHB
19 Decreased shRNA abundance (Z-score < -2) GR00366-A-53 10.48 KRAS PHB PIK3CA TSG101 BRCA1
20 Decreased shRNA abundance (Z-score < -2) GR00366-A-60 10.48 PIK3CA
21 Decreased shRNA abundance (Z-score < -2) GR00366-A-66 10.48 KRAS
22 Decreased shRNA abundance (Z-score < -2) GR00366-A-71 10.48 BRCA1
23 Decreased viability GR00055-A-2 10.39 PIK3CA KRAS
24 Decreased viability GR00106-A-0 10.39 KRAS
25 Decreased viability GR00221-A-1 10.39 AKT1 KRAS PIK3CA
26 Decreased viability GR00221-A-2 10.39 AKT1 BRCA1 PIK3CA CHEK2 KRAS
27 Decreased viability GR00221-A-3 10.39 AKT1 BRCA1 CHEK2
28 Decreased viability GR00221-A-4 10.39 AKT1 CHEK2 PIK3CA
29 Decreased viability GR00301-A 10.39 BRCA1 KRAS
30 Decreased viability GR00342-S-2 10.39 CHEK2
31 Decreased viability GR00381-A-1 10.39 KRAS
32 Decreased viability in esophageal squamous lineage GR00235-A 10.06 TP53 TSG101 BRCA1 BRCA2 CDH1 CHEK2
33 Decreased ionizing radiation sensitivity GR00232-A-1 10.03 AKT1 ATM BARD1 BRCA1 BRCA2 BRIP1
34 Synthetic lethal with MLN4924 (a NAE inhibitor) GR00250-A-1 10.02 XRCC3 AKT1 ATM BARD1 BRCA1 BRCA2
35 Synthetic lethal with MLN4924 (a NAE inhibitor) GR00250-A-2 10.02 XRCC3 AKT1 ATM BARD1 BRCA1 BRCA2
36 Increased viability with MLN4924 (a NAE inhibitor) GR00250-A-3 9.97 RAD51 RAD54L TP53 TSG101 XRCC3 ATM
37 Decreased viability with cisplatin GR00101-A-4 9.65 BARD1 BRCA1 BRCA2 BRIP1 RAD51
38 Synthetic lethal with cisplatin GR00101-A-1 9.43 BARD1 BRCA1 BRCA2 BRIP1 RAD51 XRCC3

MGI Mouse Phenotypes related to Breast Cancer:

44 (show all 14)
id Description MGI Source Accession Score Top Affiliating Genes
1 cellular MP:0005384 10.45 AKT1 ATM BARD1 BRCA1 BRCA2 BRIP1
2 endocrine/exocrine gland MP:0005379 10.34 CASP8 CDH1 CHEK2 HMMR KRAS PHB
3 embryo MP:0005380 10.32 ATM BARD1 BRCA1 BRCA2 CASP8 CDH1
4 growth/size/body region MP:0005378 10.32 AKT1 ATM BARD1 BRCA1 BRCA2 CASP8
5 homeostasis/metabolism MP:0005376 10.31 BRCA2 BRIP1 CASP8 CDH1 CHEK2 KRAS
6 mortality/aging MP:0010768 10.28 AKT1 ATM BARD1 BRCA1 BRCA2 CASP8
7 cardiovascular system MP:0005385 10.24 CASP8 CDH1 KRAS PALB2 PIK3CA RB1CC1
8 immune system MP:0005387 10.22 KRAS PIK3CA RAD54L RB1CC1 TP53 XRCC3
9 hematopoietic system MP:0005397 10.2 AKT1 ATM BRCA1 BRCA2 CASP8 CHEK2
10 integument MP:0010771 10.18 AKT1 ATM BRCA1 BRCA2 CASP8 CDH1
11 neoplasm MP:0002006 10.13 CHEK2 HMMR KRAS PALB2 PIK3CA TP53
12 nervous system MP:0003631 9.93 CHEK2 KRAS PALB2 PIK3CA TP53 AKT1
13 normal MP:0002873 9.61 AKT1 BARD1 BRCA1 BRCA2 CDH1 KRAS
14 reproductive system MP:0005389 9.36 BRIP1 CDH1 HMMR KRAS PHB PIK3CA

Drugs & Therapeutics for Breast Cancer

FDA approved drugs:

(show all 31)
id Drug Name Active Ingredient(s) 17 Company Approval Date
1
Abraxane 17 46 PACLITAXEL Celgene Approved October 2012
2
Afinitor 17 46 EVEROLIMUS Novartis Approved March 2009
3
Aredia 17 46 PAMIDRONATE DISODIUM Chiron Approved August 1996
4
Arimidex 17 46 ANASTROZOLE AstraZeneca Approved January 1996
5
Aromasin Tablets 17 46 EXEMESTANE Pharmacia & Upjohn Approved October 21. 1999
6
CEA-Scan 17 Immunomedics Approved April 1996
7
Ellence 17 46 EPIRUBICIN HYDROCHLORIDE Pharmacia & Upjohn Approved September 1999
8
Evista 17 46 RALOXIFENE HYDROCHLORIDE Eli Lilly Approved September 2007
9
Faslodex 17 46 FULVESTRANT AstraZeneca Approved April 2002
10
Femara 17 46 LETROZOLE Novartis Approved January 2001
11
Halaven 17 46 ERIBULIN MESYLATE Eisai Approved November 2010
12
Herceptin 17 46 TRASTUZUMAB Genentech Approved October 1998
13
Ibrance 17 46 PALBOCICLIB Pfizer Approved February 2015
14
Inform HER-2/neu breast cancer test 17 Oncor Approved January 1998
15
Iressa 17 46 GEFITINIB AstraZeneca Approved May 2003
16
Ixempra 17 46 IXABEPILONE Bristol-Myers Squibb Approved October 2007
17
Kadcyla 17 46 ADO-TRASTUZUMAB EMTANSINE Genentech Approved February 2013
18
Miraluma Test 17 TECHNETIUM TC-99M SESTAMIBI KIT DuPont Merck Pharmaceutical Company Approved May 1997
19
Neulasta 17 PEGFILGRASTIM Amgen Approved January 2002
20
Neutroval 17 tbo-filgrastim Teva Pharmaceutical Approved August 2012
21
Nolvadex 17 46 TAMOXIFEN CITRATE AstraZeneca Approved October 1998
22
Perjeta 17 46 PERTUZUMAB Genentech Approved June 2012
23
Premarin 17 ESTROGENS CONJUGATED Wyeth Approved July of 2003
24
Self-examination breast pad 17 Inventive Products Approved on December 22, 1995
25
Taxol 17 46 PACLITAXEL Bristol-Myers Squibb Approved August 1997
26
Taxotere 17 46 DOCETAXEL Rhone Poulenc Rorer Approved May 1996
27
Tykerb 17 46 LAPATINIB DITOSYLATE GlaxoSmithKline Approved March 2007
28
Xeloda 17 46 CAPECITABINE Roche Approved April 1998/ Approved May 2001
29
Xgeva 17 46 DENOSUMAB Amgen Approved June 2013/ Approved November 2010
30
Zoladex 17 46 GOSERELIN ACETATE AstraZeneca Approved January 1996
31
Zometa 17 46 ZOLEDRONIC ACID Novartis Approved August 2001/ Approved February 2002

Drugs for Breast Cancer (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 913)
id Name Status Phase Clinical Trials Cas Number PubChem Id
1
Estradiol Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1 50-28-2 5757 53477783
2
Medroxyprogesterone acetate Approved, Investigational Phase 4,Phase 3,Phase 2 71-58-9
3
Progesterone Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 57-83-0 5994
4
Letrozole Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 112809-51-5 3902
5
Paclitaxel Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 33069-62-4 36314
6
Zoledronic acid Approved Phase 4,Phase 3,Phase 2,Phase 1 118072-93-8 68740
7
Toremifene Approved, Investigational Phase 4,Phase 3,Phase 2 89778-26-7 3005573
8
Anastrozole Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 120511-73-1 2187
9
Exemestane Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 107868-30-4 60198
10
Tamoxifen Approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 10540-29-1 2733526
11
Diazepam Approved, Illicit, Vet_approved Phase 4,Phase 2 439-14-5 3016
12
Trastuzumab Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 180288-69-1 9903
13
Lenograstim Approved Phase 4,Phase 3,Phase 2,Phase 1 135968-09-1
14
Cyclophosphamide Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 50-18-0, 6055-19-2 2907
15
Doxorubicin Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 23214-92-8 31703
16
Carboplatin Approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 41575-94-4 10339178 498142 38904
17
Epirubicin Approved Phase 4,Phase 3,Phase 2,Phase 1 56420-45-2 41867
18
Chlorhexidine Approved, Vet_approved Phase 4 55-56-1 9552079 2713
19
Ethanol Approved Phase 4,Phase 3,Phase 2,Phase 1 64-17-5 702
20
Povidone-iodine Approved Phase 4,Phase 3 25655-41-8
21
Fluorouracil Approved Phase 4,Phase 3,Phase 2,Phase 1 51-21-8 3385
22
Capecitabine Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 154361-50-9 60953
23
Bicalutamide Approved Phase 4,Phase 3,Phase 2,Phase 1 90357-06-5 56069 2375
24
Everolimus Approved Phase 4,Phase 3,Phase 1,Phase 2 159351-69-6 6442177
25
Miconazole Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 1,Phase 2 22916-47-8 4189
26
Sirolimus Approved, Investigational Phase 4,Phase 3,Phase 1,Phase 2 53123-88-9 5284616 6436030 46835353
27
Benzocaine Approved Phase 4,Phase 3,Phase 2,Phase 1 1994-09-7, 94-09-7 2337
28
Sevoflurane Approved, Vet_approved Phase 4,Phase 3,Phase 2 28523-86-6 5206
29
Vinblastine Approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 865-21-4 13342 241903
30
Vinorelbine Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 71486-22-1 60780 44424639
31
Bevacizumab Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 216974-75-3
32
Nitrous oxide Approved, Vet_approved Phase 4,Phase 3 10024-97-2 948
33
Lidocaine Approved, Vet_approved Phase 4,Phase 3,Phase 2 137-58-6 3676
34
Palbociclib Approved Phase 4,Phase 3,Phase 2,Phase 1 571190-30-2 11431660 5005498 5330286
35
Propofol Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 2 2078-54-8 4943
36
Fulvestrant Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 129453-61-8 104741 17756771
37
Technetium tc 99m sulfur colloid Approved Phase 4
38
Pertuzumab Approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 145040-37-5, 380610-27-5 2540
39
Goserelin Approved Phase 4,Phase 3,Phase 2,Phase 1 65807-02-5 47725 5311128
40
Copper Approved Phase 4,Phase 2 15158-11-9, 7440-50-8 27099
41
Levonorgestrel Approved, Investigational Phase 4 797-63-7, 17489-40-6 13109
42
Aprepitant Approved, Investigational Phase 4,Phase 3,Phase 1 170729-80-3 151165 6918365
43
Dexamethasone Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1 50-02-2 5743
44
Fosaprepitant Approved Phase 4,Phase 3,Phase 1 172673-20-0 219090
45
Granisetron Approved, Investigational Phase 4,Phase 3 109889-09-0 3510
46
Ondansetron Approved Phase 4,Phase 3,Phase 2 99614-02-5 4595
47
Tropisetron Approved, Investigational Phase 4 105826-92-4, 89565-68-4 5595
48
Pamidronate Approved Phase 4,Phase 3,Phase 2 40391-99-9 4674
49
Isoflurane Approved, Vet_approved Phase 4 26675-46-7 3763
50
Bupropion Approved Phase 4 34841-39-9, 34911-55-2 444

Interventional clinical trials:

(show top 50) (show all 5448)
id Name Status NCT ID Phase
1 Multi-centre Clinical Trial on Hormone Replacement Treatment in China Unknown status NCT01698164 Phase 4
2 Benefits of Breast MRI for Predicting of Histopathologic Cell Type of Small Breast Cancer Unknown status NCT01597999 Phase 4
3 Assessment of Quality of Life, Bone Density and Safety in Postmenopausal Breast Cancer Patients With Letrozole Therapy Unknown status NCT00913016 Phase 4
4 A Clinical Trial of Paclitaxel Loaded Polymeric Micelle in Patients With Taxane-Pretreated Recurrent Breast Cancer Unknown status NCT00912639 Phase 4
5 Evaluate the Relationship of Bone Remodeling Markers for Skeletal Complications in Metastatic Breast Cancer Patients Unknown status NCT00912938 Phase 4
6 Clinical Outcomes After Letrozole Treatment According to the Estrogen Receptor Expression in Postmenopausal Women Unknown status NCT01069211 Phase 4
7 Extended Adjuvant Treatment With Letrozole in Breast Cancer Who Complete 5 Years of Toremifene Unknown status NCT01072318 Phase 4
8 Omega-3 Fatty Acids and Chemotherapy-induced Neuropathy and Inflammation in Breast Cancer Unknown status NCT01049295 Phase 4
9 Circulating miRNAs as Biomarkers of Hormone Sensitivity in Breast Cancer Unknown status NCT01612871 Phase 4
10 Study the Role of Positron Emission Mammography in Pre-surgical Planning for Breast Cancer Unknown status NCT00484614 Phase 4
11 A Study of Patients With HER2 Gene Amplified Metastatic Breast Cancer Treated With First Line Herceptin and a Taxane Unknown status NCT00097487 Phase 4
12 Yunzhi as Dietary Supplement in Breast Cancer Unknown status NCT00647075 Phase 4
13 Filgrastim or Pegfilgrastim in Preventing Neutropenia in Women Receiving Chemotherapy Following Surgery for Breast Cancer Unknown status NCT00030758 Phase 4
14 Pharmacogenetics as a Predictor of Toxicity in Pre-Menopausal Women Receiving Doxorubicin and Cyclophosphamide in Early Breast Cancer Unknown status NCT00352872 Phase 4
15 The MONET - Study: MR Mammography of Nonpalpable Breast Tumors Unknown status NCT00302120 Phase 4
16 Paclitaxel in Combination With Carboplatin Versus Paclitaxel Plus Epirubicin in Metastatic Breast Cancer Unknown status NCT02207361 Phase 4
17 Evaluation of Predictive Factors Regarding the Effectivity of Aromatase Inhibitor Therapy (PreFace) Unknown status NCT01908556 Phase 4
18 Study of the Effect of Glutamine Supplementation on Chemotherapy Induced Toxicities in Breast Cancer Patients Unknown status NCT00772824 Phase 4
19 Wound Infections in Breast Cancer Surgery After Preoperative Skin Preparation With Chlorhexidine vs. Povidone-iodine Unknown status NCT02479347 Phase 4
20 A Study of Liposomal Doxorubicin in Women With Breast Cancer Exploiting Tissue Doppler Imaging Unknown status NCT00531973 Phase 4
21 STARS Breast Trial (Study of Anastrozole and Radiotherapy Sequencing Pilot) Unknown status NCT00126360 Phase 4
22 Weekly and Every 3 Week Administration of Paclitaxel Liposome Injection in Metastatic Breast Cancer Unknown status NCT02142790 Phase 4
23 National Screening in Denmark With MR Versus Mammography and Ultrasound of Women With BRCA1 or BRCA2 Mutations Unknown status NCT00413491 Phase 4
24 EAP (Expanded Access Protocol) Of Lapatinib Combined With Capecitabine In Metastatic Breast Cancer Approved for marketing NCT00338247 Phase 4
25 Effect of Zoledronic Acid on Bone Metabolism in Patients With Bone Metastasis and Prostate or Breast Cancer Completed NCT00334139 Phase 4
26 Treatment With Zoledronic Acid in Patients With Breast Cancer, Multiple Myeloma, and Prostate Cancer With Cancer Related Bone Lesions Completed NCT00029224 Phase 4
27 Assessment of Pain and Quality of Life in Breast and Prostate Cancer Patients With Bone Metastases Completed NCT00434317 Phase 4
28 Compare the Value of Prophylactic Versus Therapeutic Breast Radiotherapy in CASODEX Completed NCT00590213 Phase 4
29 Case-Control-Study on the Breast Cancer Risk of Mirena® Compared With Copper IUDs Completed NCT00461253 Phase 4
30 Research Of Quality Of Life And Safety Outcomes Of Postmenopausal Breast Cancer Patients Switching From Tamoxifen Therapy To Aromatase Inhibitor Therapy Completed NCT00784888 Phase 4
31 Randomized Trial of Follow-up Strategies in Breast Cancer Completed NCT00156039 Phase 4
32 Incidence of Chemotherapy-Induced Nausea and Vomiting (CINV) Associated With the Docetaxel-Cyclophosphamide Regimen in Early Breast Cancer Patients Completed NCT01298193 Phase 4
33 Maintenance Treatment With Liposomal Doxorubicin (Caelyx) in Metastatic Breast Cancer Patients Completed NCT00128778 Phase 4
34 An Open Label Study of Postmenopausal Women With Oestrogen Receptor Positive Locally Advanced or Metastatic Breast Cancer Treated With Everolimus (RAD001) With Exemestane, With Exploratory Epigenetic Marker Analysis Completed NCT01743560 Phase 4
35 Will Preoperative MRI Breast in Women Under 56 Years With Breast Cancer Change Primary Treatment Completed NCT01859936 Phase 4
36 Open Label Study of Postmenopausal Women With ER and /or PgR Positive Breast Cancer Treated With Letrozole Completed NCT00237224 Phase 4
37 Pamidronate Administration in Breast Cancer Patients With Bone Metastases Completed NCT00128297 Phase 4
38 Prospective Validation Trial of Circulating Tumor Cells (CTCs) in Women With Metastatic Breast Cancer Completed NCT00493350 Phase 4
39 XeNA Study - A Study of Xeloda (Capecitabine) in Patients With Invasive Breast Cancer Completed NCT00127933 Phase 4
40 Life Quality and Mental State in Patients With Breast Cancer Completed NCT01458457 Phase 4
41 Eribulin Mesylate Phase IV Clinical Trial in Korean Patients With Metastatic or Locally Advanced Breast Cancer Completed NCT01961544 Phase 4
42 Letrozole in Treating Postmenopausal Women With Metastatic Breast Cancer Completed NCT00014638 Phase 4
43 Comparison of Sevoflurane and Isoflurane Anesthesia for Benign Breast Tumor Excision Completed NCT00575354 Phase 4
44 Comparative Efficiency of Three Regimen, CEFci, CEF and EC as Neoadjuvant Chemotherapy for Primary Breast Cancer Completed NCT01199432 Phase 4
45 Wellbutrin XL, Major Depressive Disorder and Breast Cancer Completed NCT00234195 Phase 4
46 Feasibility Study for the Determination of Oxysterols in Patients With Breast Cancer Receiving Hormonal Therapy With Tamoxifen or Not Completed NCT01553903 Phase 4
47 Efficacy and Safety of Letrozole vs. Letrozole Plus Zoledronic Acid as Endocrine Therapy Before Surgery in Postmenopausal Patients With Breast Cancer Completed NCT00375752 Phase 4
48 Arthralgia During Anastrozole Therapy for Breast Cancer Completed NCT00323479 Phase 4
49 A Study of Patients With HER2-Positive Metastatic Breast Cancer Completed NCT00105456 Phase 4
50 Breast VCEUS to Evaluate Early Response to Neoadjuvant Chemotherapy Completed NCT01817374 Phase 4

Search NIH Clinical Center for Breast Cancer

Inferred drug relations via UMLS 69 / NDF-RT 48 :


Cochrane evidence based reviews: breast neoplasms

Genetic Tests for Breast Cancer

Genetic tests related to Breast Cancer:

id Genetic test Affiliating Genes
1 Breast Cancer, Susceptibility to 29
2 Neoplasm of Breast 29
3 Breast Cancer, Early-Onset 29
4 Breast Cancer, Familial Male 29
5 Familial Cancer of Breast 29
6 Carcinoma of Male Breast 29
7 Breast Cancer, Lobular 29 24 CDH1
8 Breast Carcinoma 29
9 Neoplasm of the Breast 29
10 Breast Cancer, Somatic 24 KRAS

Anatomical Context for Breast Cancer

MalaCards organs/tissues related to Breast Cancer:

39
Breast, Bone, Lymph Node, Endothelial, Testes, Lung, Prostate

Publications for Breast Cancer

Articles related to Breast Cancer:

(show top 50) (show all 28107)
id Title Authors Year
1
ABCB1-C3435T polymorphism and breast cancer risk: a case-control study and a meta-analysis. ( 28534356 )
2017
2
BRCA1/2-negative hereditary triple-negative breast cancers exhibit BRCAness. ( 27943282 )
2017
3
Regular daily consumption of turmeric may be a complementary agent for the adjuvant treatment of hormone receptor positive breast cancer. ( 28534386 )
2017
4
miR520c blocks EMT progression of human breast cancer cells by repressing STAT3. ( 28112380 )
2017
5
Activation of Phenyl 4-(2-Oxo-3-alkylimidazolidin-1-yl)benzenesulfonates Prodrugs by CYP1A1 as New Antimitotics Targeting Breast Cancer Cells. ( 28535350 )
2017
6
HR+HER2- breast cancers with growth factor receptor-mediated EMT have a poor prognosis and lapatinib downregulates EMT in MCF-7 cells. ( 28349782 )
2017
7
A Novel Combination of Withaferin A and Sulforaphane Inhibits Epigenetic Machinery, Cellular Viability and Induces Apoptosis of Breast Cancer Cells. ( 28534825 )
2017
8
MiR-34a modulates ErbB2 in breast cancer. ( 27813227 )
2017
9
Modulation of cell death in human colorectal and breast cancer cells through a manganese chelate by involving GSH with intracellular p53 status. ( 28012015 )
2017
10
Glut1 promotes cell proliferation, migration and invasion by regulating epidermal growth factor receptor and integrin signaling in triple-negative breast cancer cells. ( 27931517 )
2017
11
RPN11 deubiquitinase promotes proliferation and migration of breast cancer cells. ( 28535005 )
2017
12
PGC-1 alpha interacts with microRNA-217 to functionally regulate breast cancer cell proliferation. ( 27916422 )
2017
13
The histone H2A isoform Hist2h2ac is a novel regulator of proliferation and epithelial-mesenchymal transition in mammary epithelial and in breast cancer cells. ( 28288875 )
2017
14
Simultaneous ATM/BRCA1/RAD51 expression variations associated with prognostic factors in Iranian sporadic breast cancer patients. ( 28058614 )
2017
15
Role of the long non-coding RNA PVT1 in the dysregulation of the ceRNA-ceRNA network in human breast cancer. ( 28187158 )
2017
16
A case report of Muir-Torre syndrome in a woman with breast cancer and MSI-Low skin squamous cell carcinoma. ( 28507641 )
2017
17
ESR1 single nucleotide polymorphism rs1062577 (c.*3804T>A) alters the susceptibility of breast cancer risk in Iranian population. ( 28216037 )
2017
18
High IKKI+ expression is associated with reduced time to recurrence and cancer specific survival in oestrogen receptor (ER)-positive breast cancer. ( 28006839 )
2017
19
MiR-222 promotes drug-resistance of breast cancer cells to adriamycin via modulation of PTEN/Akt/FOXO1 pathway. ( 27746366 )
2017
20
Actinomycin D Down-regulates SOX2 Expression and Induces Death in Breast Cancer Stem Cells. ( 28373426 )
2017
21
The degradation of EZH2 mediated by lncRNA ANCR attenuated the invasion and metastasis of breast cancer. ( 27716745 )
2017
22
The effects and mechanisms of SLC34A2 on maintaining stem cell-like phenotypes in CD147(+) breast cancer stem cells. ( 28381172 )
2017
23
Epoxy clerodane diterpene inhibits MCF-7 human breast cancer cell growth by regulating the expression of the functional apoptotic genes Cdkn2A, Rb1, mdm2 and p53. ( 28068628 )
2017
24
Cis-eQTL-based trans-ethnic meta-analysis reveals novel genes associated with breast cancer risk. ( 28362817 )
2017
25
The predictive value of Ki-67 before neoadjuvant chemotherapy for breast cancer: a systematic review and meta-analysis. ( 28075166 )
2017
26
NecroX-5 prevents breast cancer metastasis by AKT inhibition via reducing intracellular calcium levels. ( 27922686 )
2017
27
Aberrant Phosphorylation of SMAD4 Thr277-Mediated USP9x-SMAD4 Interaction by Free Fatty Acids Promotes Breast Cancer Metastasis. ( 28115363 )
2017
28
E3 Ubiquitin Ligase UBR5 Drives the Growth and Metastasis of Triple-Negative Breast Cancer. ( 28330927 )
2017
29
Prognostic significance of long noncoding RNA Z38 as a candidate biomarker in breast cancer. ( 28247935 )
2017
30
Highly favorable outcome in BRCA-mutated metastatic breast cancer patients receiving high-dose chemotherapy and autologous hematopoietic stem cell transplantation. ( 28092355 )
2017
31
NHERF1 inhibits proliferation of triple-negative breast cancer cells by suppressing GPER signaling. ( 28535016 )
2017
32
The effects of Nobiletin, Hesperetin, and Letrozole in a combination on the activity and expression of aromatase in breast cancer cells. ( 28364779 )
2017
33
Hair keratin KRT81 is expressed in normal and breast cancer cells and contributes to their invasiveness. ( 28405679 )
2017
34
Glutaminase expression is a poor prognostic factor in node-positive triple-negative breast cancer patients with a high level of tumor-infiltrating lymphocytes. ( 28185053 )
2017
35
PALB2-Positive Breast Cancer in a 40-Year-Old Man. ( 28090623 )
2017
36
Dub3 inhibition suppresses breast cancer invasion and metastasis by promoting Snail1 degradation. ( 28198361 )
2017
37
AQP5 Variants Affect Tumoral Expression of AQP5 and Survival in Patients with Early Breast Cancer. ( 27978515 )
2017
38
EYA1's Conformation Specificity in Dephosphorylating Phosphothreonine in Myc and Its Activity on Myc Stabilization in Breast Cancer. ( 27795300 )
2017
39
Programmed Death Ligand 1 (PD-L1) Tumor Expression Is Associated with a Better Prognosis and Diabetic Disease in Triple Negative Breast Cancer Patients. ( 28230773 )
2017
40
Prognostic significance of TRAIL-R3 and CCR-2 expression in tumor epithelial cells of patients with early breast cancer. ( 28420351 )
2017
41
The long non-coding RNA lncFOXO1 suppresses growth of human breast cancer cells through association with BAP1. ( 28339037 )
2017
42
Inhibition of RAB1A suppresses epithelial-mesenchymal transition and proliferation of triple-negative breast cancer cells. ( 28184936 )
2017
43
Silencing BMI1 radiosensitizes human breast cancer cells by inducing DNA damage and autophagy. ( 28260023 )
2017
44
Cumulative review and meta-analyses on the association between MTHFR rs1801133 polymorphism and breast cancer risk: a pooled analysis of 83 studies with 74,019 participants. ( 27824246 )
2017
45
miR-204 regulates the biological behavior of breast cancer MCF-7 cells by directly targeting FOXA1. ( 28534958 )
2017
46
KLF4 and NANOG are prognostic biomarkers for triple-negative breast cancer. ( 27300169 )
2017
47
Prognostic values of Ki-67 in neoadjuvant setting for breast cancer: a systematic review and meta-analysis. ( 28088868 )
2017
48
Amplification and the clinical significance of circulating cell-free DNA of PVT1 in breast cancer. ( 28534994 )
2017
49
Loss of DLG5 promotes breast cancer malignancy by inhibiting the Hippo signaling pathway. ( 28169360 )
2017
50
Gonadotropin-releasing hormone analogues for the prevention of chemotherapy-induced premature ovarian failure in breast cancer patients. ( 28398024 )
2017